Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

The use of serial serum measurements of the carbohydrate antigen 19-9 (CA19-9) to guide treatment decisions and serve as a surrogate end point in clinical trial design requires further validation. We investigated whether CA19-9 decline represents an accurate surrogate for survival and time to treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, A H, Hwang, J, Venook, A P, Abbruzzese, J L, Bergsland, E K, Tempero, M A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361548/
https://www.ncbi.nlm.nih.gov/pubmed/15999098
http://dx.doi.org/10.1038/sj.bjc.6602687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361548/
https://www.ncbi.nlm.nih.gov/pubmed/15999098
http://dx.doi.org/10.1038/sj.bjc.6602687

Ejemplares similares